BIOMAT Database Logo BIOMAT Database Logo

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. 2010

Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA. wang.liewei@mayo.edu

Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in the CYP19 gene may alter the effectiveness of AI therapy in the neoadjuvant setting. Genomic DNA was obtained for sequencing from 52 women pre-AI and post-AI treatment in this setting. Additionally, genomic DNA obtained from 82 samples of breast cancer and 19 samples of normal breast tissue was subjected to resequencing. No differences in CYP19 sequence were observed between tumor and germ-line DNA in the same patient. A total of 48 SNPs were identified including 4 novel SNPs when compared with previous resequencing data. For genotype-phenotype association studies, we determined the levels of aromatase activity, estrone, estradiol, and tumor size in patients pre-AI and post-AI treatment. We defined two tightly linked SNPs (rs6493497 and rs7176005 in the 5'-flanking region of CYP19 exon 1.1) that were significantly associated with a greater change in aromatase activity after AI treatment. In a follow-up study of 200 women with early-stage breast cancer who were treated with adjuvant anastrozole, these same two SNPs were also associated with higher plasma estradiol levels in patients pre-AI and post-AI treatment. Electrophoretic mobility shift and reporter gene assays confirmed likely functional effects of these two SNPs on transcription of CYP19. Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001141 Aromatase An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system. CYP19,Cytochrome P-450 CYP19,Cytochrome P-450(AROM),Androstenedione Aromatase,CYP 19,CYP19 Protein,Cytochrome P450 19,Estrogen Synthase,Estrogen Synthetase,P450AROM,Aromatase, Androstenedione,Cytochrome P 450 CYP19,Protein, CYP19
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D047072 Aromatase Inhibitors Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. Aromatase Inhibitor,Inhibitor, Aromatase,Inhibitors, Aromatase

Related Publications

Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
February 2000, Carcinogenesis,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
June 2012, Breast cancer research and treatment,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
March 2015, Breast cancer research : BCR,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Genetic variants of CYP19 (aromatase) and breast cancer risk.
March 2000, Oncogene,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.
February 1999, British journal of cancer,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity.
April 2004, Cancer letters,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Aromatase inhibitors in breast cancer therapy.
April 2002, Expert review of anticancer therapy,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
[Aromatase inhibitors in breast cancer therapy].
January 2004, Duodecim; laaketieteellinen aikakauskirja,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Aromatase inhibitors in breast cancer therapy.
November 2003, Clinical breast cancer,
Liewei Wang, and Katarzyna A Ellsworth, and Irene Moon, and Linda L Pelleymounter, and Bruce W Eckloff, and Yvette N Martin, and Brooke L Fridley, and Gregory D Jenkins, and Anthony Batzler, and Vera J Suman, and Saranya Ravi, and J Michael Dixon, and William R Miller, and Eric D Wieben, and Aman Buzdar, and Richard M Weinshilboum, and James N Ingle
Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.
March 2013, Cancer,
Copied contents to your clipboard!